CL2008002025A1 - Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados. - Google Patents

Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.

Info

Publication number
CL2008002025A1
CL2008002025A1 CL2008002025A CL2008002025A CL2008002025A1 CL 2008002025 A1 CL2008002025 A1 CL 2008002025A1 CL 2008002025 A CL2008002025 A CL 2008002025A CL 2008002025 A CL2008002025 A CL 2008002025A CL 2008002025 A1 CL2008002025 A1 CL 2008002025A1
Authority
CL
Chile
Prior art keywords
telbivudine
hepatitis
people
treatment
useful
Prior art date
Application number
CL2008002025A
Other languages
English (en)
Inventor
Nabila Sekkat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38724394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002025(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008002025A1 publication Critical patent/CL2008002025A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Soluciones farmacéuticas orales que comprenden telbivudina destinadas al tratamiento de la hepatitis B en la población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.
CL2008002025A 2007-07-12 2008-07-11 Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados. CL2008002025A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112381 2007-07-12

Publications (1)

Publication Number Publication Date
CL2008002025A1 true CL2008002025A1 (es) 2009-05-08

Family

ID=38724394

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002025A CL2008002025A1 (es) 2007-07-12 2008-07-11 Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.

Country Status (22)

Country Link
US (1) US8445457B2 (es)
EP (1) EP2178503A1 (es)
JP (1) JP5314014B2 (es)
KR (3) KR20140019040A (es)
CN (1) CN101686938B (es)
AR (1) AR067630A1 (es)
AU (1) AU2008274170B2 (es)
BR (1) BRPI0815562A2 (es)
CA (1) CA2693609A1 (es)
CL (1) CL2008002025A1 (es)
CO (1) CO6270204A2 (es)
EC (1) ECSP109871A (es)
IL (1) IL202961A (es)
MA (1) MA31507B1 (es)
MY (1) MY147366A (es)
NZ (1) NZ582443A (es)
PE (2) PE20130180A1 (es)
RU (1) RU2493826C2 (es)
TN (1) TN2010000008A1 (es)
TW (1) TW200911302A (es)
WO (1) WO2009007426A1 (es)
ZA (1) ZA200908993B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835835C (en) 2011-05-13 2019-04-02 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
MA40434B1 (fr) 2014-05-15 2019-09-30 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
WO2016173487A1 (en) * 2015-04-26 2016-11-03 Cheng-Jui Lin Method for improving kidney and/or heart function in patients with kidney disease
CN107550866A (zh) * 2016-06-30 2018-01-09 康普药业股份有限公司 一种替比夫定制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
AU9186398A (en) 1997-09-26 1999-04-23 Wakamoto Pharmaceutical Co., Ltd. Aqueous preparation containing antiviral agent having purine or pyrimidine skeleton
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
DE19817265A1 (de) 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
PE20030545A1 (es) 2001-10-31 2003-06-19 Schering Corp Formulaciones de jarabe de ribavirina
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates

Also Published As

Publication number Publication date
US8445457B2 (en) 2013-05-21
TW200911302A (en) 2009-03-16
MY147366A (en) 2012-11-30
WO2009007426A1 (en) 2009-01-15
CN101686938A (zh) 2010-03-31
KR20140019040A (ko) 2014-02-13
CO6270204A2 (es) 2011-04-20
AU2008274170B2 (en) 2011-06-09
MA31507B1 (fr) 2010-07-01
AU2008274170A1 (en) 2009-01-15
IL202961A (en) 2013-10-31
NZ582443A (en) 2011-04-29
JP5314014B2 (ja) 2013-10-16
PE20130180A1 (es) 2013-03-06
BRPI0815562A2 (pt) 2015-02-18
KR20100029829A (ko) 2010-03-17
JP2010533146A (ja) 2010-10-21
RU2010104395A (ru) 2011-08-20
US20100197629A1 (en) 2010-08-05
RU2493826C2 (ru) 2013-09-27
KR20120078754A (ko) 2012-07-10
ECSP109871A (es) 2010-02-26
AR067630A1 (es) 2009-10-21
PE20090476A1 (es) 2009-05-12
TN2010000008A1 (en) 2011-09-26
ZA200908993B (en) 2010-09-29
CA2693609A1 (en) 2009-01-15
EP2178503A1 (en) 2010-04-28
CN101686938B (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
FR2878159B1 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
DE50212546D1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
CY1116599T1 (el) Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που περιλαμβανουν εστερα φουμαρικου οξεος
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
EP2364144A4 (en) PHARMACEUTICAL FORM FOR ADMINISTRATION THROUGH THE MOUTH
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
HN2003000185A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso.
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
CL2008002025A1 (es) Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PE20060588A1 (es) Composiciones farmaceuticas que contienen flibanserina
NO20034863D0 (no) Deuterert 3-piperidinopropiofenon og medikamenter inneholdende disse
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
AR061668A1 (es) Jarabes antihistaminicos, estables al almacenamiento, sin azucar
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
ATE474561T1 (de) Orodispersible pharmazeutische zusammensetzung für die orale, oromukosale oder sublinguale verabreichung von agomelatin
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
AR023815A1 (es) Solucion oral de prucalopride
CL2011000439A1 (es) Formulacion farmaceutica que consiste esencialmente de 50 mg/ml de clorhidrato de canfosfamida en 100 mm de un amortiguador acuoso de citrato de sodio a ph 4,6; formulacion liofilizada que la comprende; y metodo de preparacion de la formulacion farmaceutica.
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.